GlassScriptPhysician profile
Jonathan T Wong
NPI 1265473789
$5,079.82
in general payments reported to CMS, 2019-2025
20 companies · $1,855 in 2025
The $1,855 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $249 · 2021: $277 · 2022: $716 · 2023: $556 · 2024: $923 · 2025: $1,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Entertainment: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.92 |
| Entertainment | $584.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,214.76 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Optos, INC. | $815.74 | 2022-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $575.72 | 2025 | Photrexa Viscous and Photrexa, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $358.74 | 2019-2021 | |
| Coopervision INC. | $323.40 | 2021-2024 | Myday Contact Lens |
| Dompe US, INC. | $237.59 | 2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $203.69 | 2025 | |
| Abb Con-Cise Optical Group LLC | $183.28 | 2023-2024 | Contact Lens, Spectacle Lenses |
| Apellis Pharmaceuticals, INC. | $146.17 | 2025 | |
| Amgen INC. | $143.28 | 2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $123.41 | 2023 | |
| Astellas Pharma US INC | $121.86 | 2025 | Izervay |
| Alexion Pharmaceuticals, INC. | $121.86 | 2025 | Ultomiris |
| Biotissue Holdings INC. | $103.83 | 2024 | |
| Bausch & Lomb Americas INC. | $101.80 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $98.55 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $90.68 | 2019 | |
| Lkc Technologies, INC. | $76.28 | 2025 | |
| Shire North American Group INC | $22.46 | 2019 | |
| Abbvie INC. | $16.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.